Berliner Boersenzeitung - Bulletin from the extraordinary general meeting in Immunovia AB

EUR -
AED 3.999906
AFN 76.797516
ALL 101.247602
AMD 438.743527
ANG 1.963666
AOA 906.268709
ARS 394.499124
AUD 1.633816
AWG 1.9634
AZN 1.856075
BAM 1.955548
BBD 2.200017
BDT 120.124538
BGN 1.958177
BHD 0.412308
BIF 3098.95834
BMD 1.089265
BND 1.456812
BOB 7.5291
BRL 5.31627
BSD 1.08956
BTN 90.736154
BWP 14.744102
BYN 3.589838
BYR 21349.589966
BZD 2.196317
CAD 1.470236
CDF 2908.337395
CHF 0.947735
CLF 0.033918
CLP 935.907635
CNY 7.703503
COP 4318.107068
CRC 576.601961
CUC 1.089265
CUP 28.865517
CVE 110.564621
CZK 24.294204
DJF 193.584568
DKK 7.461142
DOP 61.925132
DZD 146.942917
EGP 33.776257
ERN 16.338972
ETB 60.676271
FJD 2.419044
FKP 0.861997
GBP 0.857756
GEL 2.935612
GGP 0.861997
GHS 13.071565
GIP 0.861997
GMD 73.311718
GNF 9373.123941
GTQ 8.534549
GYD 227.960658
HKD 8.509283
HNL 26.909024
HRK 7.670134
HTG 144.211438
HUF 379.086356
IDR 16788.45703
ILS 4.048988
IMP 0.861997
INR 90.647364
IQD 1426.93688
IRR 46035.057524
ISK 151.223052
JEP 0.861997
JMD 168.391369
JOD 0.772729
JPY 159.920454
KES 166.930249
KGS 97.14663
KHR 4486.682069
KMF 491.74901
KPW 980.276955
KRW 1410.418223
KWD 0.336289
KYD 0.907983
KZT 502.864499
LAK 22547.78162
LBP 16385.156917
LKR 357.68396
LRD 204.945587
LSL 20.391453
LTL 3.216316
LVL 0.658886
LYD 5.244853
MAD 10.980338
MDL 19.340688
MGA 4901.691952
MKD 61.61207
MMK 2288.205471
MNT 3760.199955
MOP 8.769371
MRO 388.867344
MUR 48.352877
MVR 16.731519
MWK 1834.870618
MXN 18.72098
MYR 5.090177
MZN 68.895944
NAD 20.271629
NGN 859.430297
NIO 40.046862
NOK 11.701792
NPR 145.177646
NZD 1.754615
OMR 0.421215
PAB 1.089615
PEN 4.072803
PGK 4.06721
PHP 60.290266
PKR 310.685593
PLN 4.328761
PYG 8106.621645
QAR 3.965741
RON 4.957286
RSD 117.363212
RUB 99.368223
RWF 1357.223934
SAR 4.086048
SBD 9.232549
SCR 14.634947
SDG 654.648511
SEK 11.362976
SGD 1.452648
SHP 1.325363
SLE 24.762839
SLL 21512.980054
SOS 622.518821
SRD 41.191097
STD 22545.582023
SYP 14161.522499
SZL 20.39144
THB 37.983066
TJS 11.914374
TMT 3.823319
TND 3.390923
TOP 2.5686
TRY 31.479539
TTD 7.392116
TWD 34.049369
TZS 2739.501323
UAH 39.735485
UGX 4143.46667
USD 1.089265
UYU 42.604516
UZS 13403.403657
VEF 3860142.930966
VES 38.634829
VND 26469.134499
VUV 129.846293
WST 2.977169
XAF 655.872579
XAG 0.042742
XAU 0.000526
XCD 2.943793
XDR 0.818695
XOF 654.648503
XPF 119.656134
YER 272.697837
ZAR 20.324378
ZMK 9804.694177
ZMW 25.878907
ZWL 350.742819
  • SCU

    -0.0300

    12.72

    -0.24%

  • NGG

    0.8300

    66.84

    +1.24%

  • SCS

    0.1500

    12.46

    +1.2%

  • RIO

    2.0700

    71.16

    +2.91%

  • SLAC

    0.0390

    10.29

    +0.38%

  • GSK

    0.5800

    36.57

    +1.59%

  • CMSC

    0.0600

    24.61

    +0.24%

  • JRI

    0.2100

    11.28

    +1.86%

  • CMSD

    0.1800

    24.33

    +0.74%

  • AZN

    0.2000

    64.79

    +0.31%

  • BCC

    3.0900

    112.39

    +2.75%

  • BCE

    0.9200

    40.31

    +2.28%

  • RELX

    -0.0200

    38.56

    -0.05%

  • RYCEF

    0.1043

    3.53

    +2.95%

  • BP

    -0.3100

    35.98

    -0.86%

  • RBGPF

    0.3720

    68.01

    +0.55%

  • BTI

    0.1500

    32.04

    +0.47%

  • VOD

    0.1600

    9.22

    +1.74%

Bulletin from the extraordinary general meeting in Immunovia AB
Bulletin from the extraordinary general meeting in Immunovia AB

Bulletin from the extraordinary general meeting in Immunovia AB

LUND, Sweden, Nov. 21, 2023 /PRNewswire/ -- On 21st November 2023, an extraordinary general meeting ("EGM") was held in Immunovia AB (publ), 556730-4299, at Medicon Village in Lund. Below is a summary of the resolutions made at the AGM. 

Text size:

Election of new board members 

The meeting resolved, in accordance with the nomination committee's proposal, (i) that the number of board members shall be six, with no deputy members, and (ii) to elect Melissa Farina and Valerie Bogdan-Powers as new board members. For the time up until the next annual general meeting, the board will consist of Peter Høngaard Andersen (chair), Hans Johansson, Michael Löfman, Martin Møller, Melissa Farina and Valerie Bogdan-Powers

Fees for the board and committees 

The meeting resolved, in accordance with the nomination committee's proposal, that the remuneration resolved by the Annual General Meeting 2023 to the board members elected by the Annual General Meeting 2023 for the period from their election to the Extraordinary General Meeting shall be paid in proportion to the length of their respective terms of office. The meeting further resolved that remuneration for work within the board to each of the current board members elected by the Annual General Meeting 2023 and to each of the newly elected board members shall be SEK 180,000 (on an annual basis) and for the Chair SEK 420,000 (on an annual basis), and that the remuneration to these members for the period from the time their election takes effect until the end of the next Annual General Meeting shall be paid in proportion to the length of their respective terms of office. 

Furthermore, it was resolved that the Chair of the Audit, Science and Remuneration Committee should be remunerated with SEK 40,000 and other members of said committees to be remunerated with SEK 25,000 (on an annual basis), and that the remuneration to these members for the period from the time their election takes effect until the end of the next Annual General Meeting shall be paid in proportion to the length of their respective terms of office. Finally, it was resolved that the board members should be compensated for reasonable travel expenses in accordance with the company's travel policy. 

Equity incentive program for the Company's management and key personnel 

The meeting resolved, in accordance with the board of directors' proposal, to adopt an equity incentive program for the Company's management and key personnel, including a resolution to issue not more than 2,597,234 warrants to ensure the delivery of shares to the participants and for hedging of social security costs. The incentive program entails that the participants will be granted options which entitles the holder to purchase shares in the company at a pre-determined exercise price corresponding to 100 percent of the volume-weighted average price of the Immunovia share on Nasdaq Stockholm during the five (5) trading days preceding the granting date. 

Equity incentive program for the Company's board of directors 

The meeting resolved, in accordance with the nomination committee's proposal, to adopt an equity incentive program for the Company's board of directors, including a resolution to issue not more than 649,309 warrants to ensure the delivery of shares to the participants and for hedging of social security costs. The incentive program entails that the participants will be granted options which entitles the holder to purchase shares in the company at a pre-determined exercise price corresponding to 100 percent of the volume-weighted average price of the Immunovia share on Nasdaq Stockholm during the five (5) trading days preceding the granting date. 

For more information, please contact: 

Jeff Borcherding 
President and Chief Executive Officer 
[email protected] 

Karin Almqvist Liwendahl 
Chief Financial Officer 
[email protected] 
+46 709 11 56 08 

The information was submitted for publication, through the agency of the contact persons set out above, at [11.30] CET on 21st November 2023. 

Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.  

The following files are available for download:

 

(O.Joost--BBZ)